Literature DB >> 19678795

Metformin: diamonds are forever.

N Papanas, E Maltezos, D P Mikhailidis.   

Abstract

Metformin has now been established as the drug of choice for the first-line management of type 2 diabetes mellitus. It reduces insulin resistance, improves glycaemic control, and can be safely combined with other classes of oral hypoglycaemic agents. Equally important, metformin has been shown to have a significant beneficial effect on cardiovascular morbidity. Moreover, this agent acts favourably on blood pressure, lipids, haemostasis and other features of the metabolic syndrome. Metformin also contributes to weight reduction and diabetes prevention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19678795     DOI: 10.1517/14656560903176453

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  8 in total

1.  Prebiotic fiber increases hepatic acetyl CoA carboxylase phosphorylation and suppresses glucose-dependent insulinotropic polypeptide secretion more effectively when used with metformin in obese rats.

Authors:  Kim A Pyra; Dolan C Saha; Raylene A Reimer
Journal:  J Nutr       Date:  2012-01-05       Impact factor: 4.798

2.  Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.

Authors:  Gurusamy Umamaheswaran; Ramakrishnan Geethakumari Praveen; Solai Elango Damodaran; Ashok Kumar Das; Chandrasekaran Adithan
Journal:  Clin Exp Med       Date:  2014-12-10       Impact factor: 3.984

3.  Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies.

Authors:  Hongliang Yu; Li Yin; Xuesong Jiang; Xiujin Sun; Jing Wu; Hao Tian; Xianshu Gao; Xia He
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

4.  Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes.

Authors:  Natascha Schweighofer; Bernd Genser; Winfried Maerz; Marcus E Kleber; Olivia Trummer; Thomas R Pieber; Barbara Obermayer-Pietsch
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-18       Impact factor: 3.168

Review 5.  Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review.

Authors:  Monica Franciosi; Giuseppe Lucisano; Emanuela Lapice; Giovanni F M Strippoli; Fabio Pellegrini; Antonio Nicolucci
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

6.  Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study.

Authors:  Maria-Agata Miselli; Edoardo Dalla Nora; Angelina Passaro; Franco Tomasi; Giovanni Zuliani
Journal:  Cardiovasc Diabetol       Date:  2014-10-11       Impact factor: 9.951

7.  The impact of metformin use on the risk of prostate cancer after prostate biopsy in patients with high grade intraepithelial neoplasia.

Authors:  Lucio Dell'Atti; Andrea B Galosi
Journal:  Int Braz J Urol       Date:  2018 Jan-Feb       Impact factor: 1.541

Review 8.  Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.

Authors:  Kalliopi Pafili; Michael Roden
Journal:  Mol Metab       Date:  2020-11-19       Impact factor: 7.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.